Pegcetacoplan: A New Opportunity for Complement Inhibition in PNH.

Published in: Journal of blood medicine (2023)

Pegcetacoplan is the newest inhibitor of the complement system to be approved by the FDA and EMA for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). The cyclic peptide inhibitor of C3 was evaluated in several clinical trials in PHN leading to its approval. The focus of this paper will review the efficacy and safety of Pegcetacoplan (PEG), and considerations for use in patients with PNH.

Keyphrases

clinical trial
drug administration
blood pressure
atrial fibrillation
obstructive sleep apnea
randomized controlled trial
drug delivery
physical activity
depressive symptoms
open label
combination therapy
sleep quality
catheter ablation